HIV seroprevalence among high-risk groups in kohgiloyeh and boyerahmad province, Southwest of Iran, a behavioral surveillance survey

AIDS and Behavior

Volumn 16, Issue 1, 2012, Pages 86-90

  Ilami, Orang ^a   Sarkari, Bahador ^b   Khosravani, Abdolmajid ^a   Tori, Mehdi Akbartabar ^a   Hosseini, Zahra ^a  

^a YASUJ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

High risk group; HIV; Iran; Prevalence; Seroprevalence

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEALTH SURVEY; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; IMMUNOLOGY; IRAN; MALE; PREVALENCE; QUESTIONNAIRE; SEX RATIO; SEXUAL BEHAVIOR; SOCIOECONOMICS; SUBSTANCE ABUSE;

ADULT; AGE DISTRIBUTION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEALTH SURVEYS; HIV ANTIBODIES; HIV INFECTIONS; HIV SEROPREVALENCE; HIV-1; HIV-2; HUMANS; IRAN; MALE; POPULATION SURVEILLANCE; PREVALENCE; QUESTIONNAIRES; RISK-TAKING; SEX DISTRIBUTION; SEXUAL BEHAVIOR; SOCIOECONOMIC FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

EID: 84858272214     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-010-9874-x     Document Type: Article

References (12)

1. UNAIDS epidemic update. 2009. Available at: http://data.unaids.org/pub/ Report/2009/JC1700-Epi-Update-2009-en.pdf.
2. Mathers BM, Degenhardt L, Ali H, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet. 2010; 375: 1014-28.
3. Kheirandish P, Seyedalinaghi SA, Hosseini M, et al. Prevalence and correlates of HIV infection among male injection drug users in detention in Tehran, Iran. J Acquir Immune Defic Syndr. 2010;53: 273-5.
4. Rahimi-Movaghar A, Razaghi EM, Sahimi-Izadian E, Amin-Esmaeili M. HIV, hepatitis C virus, and hepatitis B virus co-infections among injection drug users in Tehran, Iran. Int J Infect Dis. 2010;14: 28-33.
5. Abu-Raddad LJ, Hilmi N, Mumtaz G, et al. Epidemiology of HIV infection in the Middle East and North Africa. AIDS. 2010; 24 (Suppl 2): S5-23.
6. Khattak MF, Salamat N, Bhatti FA, Qureshi TZ. Seroprevalence of hepatitis B, C and HIV in blood donors in northern Pakistan. J Pak Med Assoc. 2002;52: 398-402.
7. Imani R, Karimi A, Rouzbahani R, Rouzbahani A. Seroprevalence of HBV, HCV and HIV infection among intravenous drug users in Shahr-e-Kord, Islamic Republic of Iran. East Mediterr Health J. 2008;14: 1136-41.
8. Aceijas C, Stimson GV, Hickman M, Rhodes T. Global overview of injecting drug use and HIV infection among injecting drug users. AIDS. 2004;18: 2295-303.
9. Khedmat H, Fallahian F, Abolghasemi H, et al. Seroepidemiologic study of hepatitis B virus, hepatitis C virus, human immunodeficiency virus and syphilis infections in Iranian blood donors. Pak J Biol Sci. 2007;15: 4461-6.
10. Alavian SM, Bagheri-Lankarani K, Mahdavi-Mazdeh M, Nourozi S. Hepatitis B and C in dialysis units in Iran: changing the epidemiology. Hemodial Int. 2008;12: 378-82.
11. Karimi M, Ghavanini AA. Seroprevalence of HBsAg, anti-HCV, and anti-HIV among haemophiliac patients in Shiraz, Iran. Haematologia (Budap). 2001;31: 251-5.
12. Mirmomen S, Alavian SM, Hajarizadeh B, et al. Epidemiology of hepatitis B, hepatitis C, and human immunodeficiency virus infections in patients with beta-thalassemia in Iran: a multicenter study. Arch Iran Med. 2006;9: 319-23.